Fakher Rahim1,2, Babak Arjmand3, Kiarash Shirbandi4, Moloud Payab5, Bagher Larijani6. 1. Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 2. Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 3. Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 4. Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Ahvaz, Iran. 5. Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 6. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: There is a general agreement that to ensure promising results of stem cell therapy in patients with diabetes, one must first understand its risks and benefits; thus, if the risk is sufficiently low along with many benefits, it can lead to developing a novel therapeutic approach based on sound science. METHODS: A systematic review and meta-analysis was performed using all available clinical trials to determine the benefits and risks associated with stem cell therapy in patients with diabetes (both T1DM and T2DM). An extensive search was conducted across several databases using all MeSH words regarding stem cell therapy and diabetes. RESULTS: In T2DM, a large body of research has shown that stem cell therapy has improved the insulin daily requirement and glycosylated hemoglobin (HbA1C) levels, and also has a positive effect on these variables, but has a negative impact on c-peptide. Hence, in T1DM, stem cell therapy improves c-peptide and HbA1C levels and has a positive effect on these variables, but has a negative impact on insulin daily requirement. CONCLUSIONS: A total of 639 cells have the ability to self-renew and differentiate into a variety of cells, including blood, heart, nervous and cartilage cells. Paradoxically, it has been stated that these cells also have the potential to form cancer cells. These possible risks warrant caution by both medical specialists and patients while proceeding with the treatment; thus, it is critically crucial to conduct further research on stem cell therapy but with first considering their risk and benefits.
BACKGROUND: There is a general agreement that to ensure promising results of stem cell therapy in patients with diabetes, one must first understand its risks and benefits; thus, if the risk is sufficiently low along with many benefits, it can lead to developing a novel therapeutic approach based on sound science. METHODS: A systematic review and meta-analysis was performed using all available clinical trials to determine the benefits and risks associated with stem cell therapy in patients with diabetes (both T1DM and T2DM). An extensive search was conducted across several databases using all MeSH words regarding stem cell therapy and diabetes. RESULTS: In T2DM, a large body of research has shown that stem cell therapy has improved the insulin daily requirement and glycosylated hemoglobin (HbA1C) levels, and also has a positive effect on these variables, but has a negative impact on c-peptide. Hence, in T1DM, stem cell therapy improves c-peptide and HbA1C levels and has a positive effect on these variables, but has a negative impact on insulin daily requirement. CONCLUSIONS: A total of 639 cells have the ability to self-renew and differentiate into a variety of cells, including blood, heart, nervous and cartilage cells. Paradoxically, it has been stated that these cells also have the potential to form cancer cells. These possible risks warrant caution by both medical specialists and patients while proceeding with the treatment; thus, it is critically crucial to conduct further research on stem cell therapy but with first considering their risk and benefits.
Entities:
Keywords:
Type 2 diabetes mellitus (T2DM); glycosylated hemoglobin (HbA1C); stem cells; type 1 diabetes mellitus (T1DM)
Authors: E Snarski; A Milczarczyk; T Torosian; M Paluszewska; E Urbanowska; M Król; P Boguradzki; K Jedynasty; E Franek; W Wiktor-Jedrzejczak Journal: Bone Marrow Transplant Date: 2010-06-28 Impact factor: 5.483
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Carlos E B Couri; Maria C B Oliveira; Ana B P L Stracieri; Daniela A Moraes; Fabiano Pieroni; George M N Barros; Maria Isabel A Madeira; Kelen C R Malmegrim; Maria C Foss-Freitas; Belinda P Simões; Edson Z Martinez; Milton C Foss; Richard K Burt; Júlio C Voltarelli Journal: JAMA Date: 2009-04-15 Impact factor: 56.272
Authors: Michael J Haller; Clive H Wasserfall; Kieran M McGrail; Miriam Cintron; Todd M Brusko; John R Wingard; Susan S Kelly; Jonathan J Shuster; Mark A Atkinson; Desmond A Schatz Journal: Diabetes Care Date: 2009-11 Impact factor: 17.152
Authors: Katarzyna Waszczuk; Jolanta Kucharska-Mazur; Ernest Tyburski; Katarzyna Rek-Owodziń; Piotr Plichta; Krzysztof Rudkowski; Piotr Podwalski; Tomasz Grąźlewski; Monika Mak; Błażej Misiak; Anna Michalczyk; Maciej Tarnowski; Katarzyna Sielatycka; Angelika Szczęśniak; Karolina Łuczkowska; Barbara Dołęgowska; Marta Budkowska; Mariusz Z Ratajczak; Jerzy Samochowiec Journal: Int J Environ Res Public Health Date: 2022-05-15 Impact factor: 4.614
Authors: Liem Thanh Nguyen; Duc M Hoang; Kien T Nguyen; Duc M Bui; Hieu T Nguyen; Hong T A Le; Van T Hoang; Hue T H Bui; Phuong T M Dam; Xuan T A Hoang; Anh T L Ngo; Hang M Le; Nhi Y Phung; Duc M Vu; Trung T Duong; Tu D Nguyen; Lien T Ha; Hoa T P Bui; Hoa K Nguyen; Michael Heke; Anh V Bui Journal: Stem Cells Transl Med Date: 2021-06-03 Impact factor: 6.940